Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
Sponsor: Keymed Biosciences Co.Ltd
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-08-19
Completion Date
2027-07-21
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
CM512 injection
subcutaneous injection
Placebo
subcutaneous injection
Locations (1)
The First Clinical Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China